查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1836372

2032 年先進癌症診斷市場預測：按產品類型、癌症類型、技術、分銷管道、應用、最終用戶和地區進行全球分析

Advanced Cancer Diagnostics Market Forecasts to 2032 - Global Analysis By Product Type (Instruments, Consumables, Software & Services, and Other Product Types), Cancer Type, Technology, Distribution Channel, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，全球先進癌症診斷市場預計在 2025 年達到 641.3 億美元，到 2032 年將達到 1,249.7 億美元，預測期內的複合年成長率為 10.0%。

先進的癌症診斷涵蓋用於早期癌症檢測、腫瘤生物學分析和個人化治療策略的最新技術和方法。這些技術和方法包括生物標記分析、基因檢測、高階成像和分子分析等工具。這些診斷方法能夠準確檢測癌症，改善預後並減少治療併發症。透過支持標靶治療和精準干預措施的開發，先進的診斷技術能夠顯著改善患者護理、提高存活率和整體治療效果。

全球癌症發生率上升

隨著人口老化和生活方式相關風​​險因素的增加，早期檢測技術已成為臨床工作流程的關鍵。醫療保健系統正在投資精準腫瘤學工具，例如液態切片和分子成像，以提高診斷準確性。人工智慧病理檢測和次世代定序儀(NGS) 的創新正在促成個人化治療策略。多體學平台的整合正在將癌症診斷轉變為一門數據驅動的學科。日益成長的癌症負擔正在刺激已開發經濟體和新興經濟體的市場發展。

複雜且限制性的報銷政策

先進癌症診斷的報銷框架仍然碎片化，這常常阻礙其廣泛應用。付款方通常需要大量的臨床檢驗和成本效益數據，才能核准新的診斷測試。人工智慧和基因組技術的加入增加了監管的複雜性，減緩了報銷核准。資源和專業知識有限的小型診斷公司在應對這些政策方面面臨挑戰。這些限制可能會延遲患者獲得尖端診斷工具的機會，並扼殺創新。全球報銷標準的協調對於充分發揮精準診斷的潛力至關重要。

擴展診斷能力

診斷技術的快速發展正在開闢癌症檢測和監測的新領域。液態切片平台、人工智慧成像和即時生物標記分析正在徹底改變臨床醫生識別惡性腫瘤的方式。向非侵入式照護現場診斷的轉變正在提高患者舒適度和操作效率。新興趨勢包括穿戴式生物感測器和雲端基礎的診斷平台，可實現遠端癌症篩檢。監管機構正透過加速核准途徑和數位健康舉措加強對創新的支持。這些發展為市場成長和跨部門合作創造了肥沃的土壤。

假陽性/陰性的風險

假陽性可能導致不必要的治療和情緒困擾，而假陰性則會延誤挽救生命的干涉措施。不同平台的檢測靈敏度和特異性有差異，導致結果不一致。人工智慧演算法前景廣闊，但需要嚴格的檢驗才能確保臨床可靠性。監管機構正在加強診斷效能和數據透明度的標準。應對這些風險對於維護信任和安全地整合新興技術至關重要。

COVID-19的影響：

新冠疫情擾亂了癌症診斷服務，延誤了篩檢，並降低了患者吞吐量。封鎖和資源重新分配使實驗室運作和供應鏈緊張，導致檢測短缺。然而，這場危機加速了遠距離診斷、遠距病理學和人工智慧分診系統的採用。緊急使用授權使得創新診斷工具在疫情期間得以快速部署。後疫情時代，策略強調韌性、自動化和分散式檢查模式。這些轉變正在重塑癌症診斷格局，更加重視數位轉型和應對準備。

預計在預測期內，消耗品部分將佔據最大佔有率

由於耗材在常規診斷程序中發揮重要作用，預計在預測期內將佔據最大的市場佔有率。試劑、檢測試劑套件和樣品製備工具對於分子和免疫組織化學測試至關重要。試劑配方和微流體盒的不斷創新正在提高測試的靈敏度和通量。個人化醫療的興起推動了針對個別癌症特徵的專用耗材的需求。實驗室工作流程的自動化正在增加集中式和分散式耗材的使用。隨著全球診斷數量的增加，耗材仍是癌症檢測基礎設施的支柱。

預計在預測期內，醫院和診所部門的複合年成長率最高。

醫院和診所領域預計將在預測期內實現最高成長率，這得益於其在癌症診斷和治療中的核心作用。這些機構正在迅速採用先進的成像系統、基於人工智慧的病理學工具和整合診斷平台。對早期檢測和精準腫瘤學的追求正在推動對內部診斷能力的投資。醫院也在利用雲端基礎的數據分析來簡化工作流程並提高診斷準確性。新興趨勢包括配備即時決策支援系統的混合診斷實驗室和多學科癌症中心。隨著患者人數的增加，醫院和診所正成為癌症診斷創新的中心。

比最大的地區

受醫療基礎設施擴張和癌症發病率上升的推動，亞太地區預計將在預測期內佔據最大的市場佔有率。中國、印度和日本等國家正大力投資診斷現代化和本地製造。政府正在推動早期癌症篩檢，並津貼先進的診斷技術。該地區正見證人工智慧輔助成像和可攜式診斷設備的快速普及。全球科技公司與本地醫療服務提供者之間的策略合作夥伴關係正在加速創新和市場滲透。

複合年成長率最高的地區：

在預測期內，北美預計將呈現最高的複合年成長率，這得益於其在診斷創新和研究資金方面的領先地位。美國和加拿大正在率先開發基因組分析、人工智慧診斷和智慧實驗室系統。監管機構正在簡化尖端診斷工具的核准流程，以加快其市場准入速度。醫院正在整合物聯網和雲端基礎平台，以提高診斷準確性和營運效率。該地區受益於強大的報銷生態系統和個人化醫療的高度普及。隨著癌症治療日益以數據主導，北美將繼續在診斷卓越性方面樹立全球標竿。

免費客製化服務：

此報告的訂閱者可以使用以下免費自訂選項之一：

  • 公司簡介
    • 對最多三家其他市場公司進行全面分析
    • 主要企業的SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家進行的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 主要研究資料
    • 次級研究資訊來源
    • 先決條件

第3章市場走勢分析

  • 驅動程式
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 技術分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球高級癌症診斷市場（依產品類型）

  • 裝置
    • 影像系統
    • 基於病理學的儀器
    • 分子診斷平台
  • 耗材
    • 套件和試劑
    • 檢測組
  • 軟體和服務
    • 數據分析工具
    • 診斷服務
  • 其他產品類型

第6章全球高級癌症診斷市場（按癌症類型）

  • 乳癌
  • 肝癌
  • 肺癌
  • 子宮頸癌
  • 大腸直腸癌
  • 卵巢癌
  • 攝護腺癌
  • 其他癌症

7. 全球先進癌症診斷市場（按技術）

  • 影像技術
    • MRI
    • PET/CT
    • 電腦斷層掃描
    • 超音波
    • 乳房X光檢查
  • 分子診斷
    • PCR
    • 微陣列
    • 次世代定序（NGS）
    • 原位雜合技術（ISH）
  • 免疫檢測
    • ELISA
    • 免疫組織化學（IHC）
  • 液態生物檢體
    • 循環性腫瘤細胞（CTC）
    • 循環腫瘤DNA（ctDNA）
    • 外泌體
  • 其他技術

8. 全球高級癌症診斷市場（按分銷管道）

  • 直銷
  • 分銷商和經銷商
  • 線上平台

9. 全球先進癌症診斷市場（按應用）

  • 早期癌症篩檢
  • 檢測復發和微量殘存疾病（MRD）
  • 診斷和預後測試
  • 伴隨診斷
  • 治療方法選擇和監測
  • 其他用途

第 10 章全球進階癌症診斷市場（按最終用戶）

  • 醫院和診所
  • 門診治療中心
  • 診斷實驗室
  • 癌症研究所
  • 其他最終用戶

第 11 章全球高階癌症診斷市場（按地區）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第12章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第13章：企業概況

  • F. Hoffmann-La Roche Ltd.
  • bioMerieux SA
  • Thermo Fisher Scientific Inc.
  • Medtronic plc
  • Abbott Laboratories
  • Becton, Dickinson and Company（BD）
  • Illumina Inc.
  • Myriad Genetics Inc.
  • GE Healthcare
  • Guardant Health
  • Siemens Healthineers
  • Qiagen NV
  • Bio-Rad Laboratories Inc.
  • Hologic Inc.
  • Agilent Technologies Inc.
Product Code: SMRC31496

According to Stratistics MRC, the Global Advanced Cancer Diagnostics Market is accounted for $64.13 billion in 2025 and is expected to reach $124.97 billion by 2032 growing at a CAGR of 10.0% during the forecast period. Advanced cancer diagnostics encompass modern techniques and technologies used to identify cancers early, analyze tumor biology, and personalize treatment decisions. They involve tools such as biomarker analysis, genetic testing, advanced imaging, and molecular profiling. These diagnostic methods allow for accurate cancer detection, improved prognosis, and reduced treatment complications. By supporting targeted therapy development and precise intervention, advanced diagnostics significantly enhance patient care, survival chances, and overall treatment effectiveness.

Market Dynamics:

Driver:

Rising global cancer incidence

As aging populations grow and lifestyle-related risk factors increase, early detection technologies are becoming essential in clinical workflows. Healthcare systems are investing in precision oncology tools, including liquid biopsies and molecular imaging, to improve diagnostic accuracy. Innovations in AI-powered pathology and next-generation sequencing (NGS) are enabling personalized treatment strategies. The integration of multi-omics platforms is transforming cancer diagnostics into a data-driven discipline. This rising burden of cancer is catalyzing market expansion across both developed and emerging economies.

Restraint:

Complex and restrictive reimbursement policies

Reimbursement frameworks for advanced cancer diagnostics remain fragmented and often hinder widespread adoption. Payers frequently require extensive clinical validation and cost-effectiveness data before approving coverage for novel diagnostic tests. The inclusion of AI and genomic technologies adds regulatory complexity, slowing reimbursement approvals. Smaller diagnostic firms face challenges navigating these policies due to limited resources and expertise. These constraints can delay patient access to cutting-edge diagnostic tools and stifle innovation. Harmonizing global reimbursement standards is critical to unlocking the full potential of precision diagnostics.

Opportunity:

Expanding diagnostic capabilities

Rapid advancements in diagnostic technologies are opening new frontiers in cancer detection and monitoring. Liquid biopsy platforms, AI-enhanced imaging, and real-time biomarker analysis are revolutionizing how clinicians identify malignancies. The shift toward non-invasive and point-of-care diagnostics is improving patient comfort and operational efficiency. Emerging trends include wearable biosensors and cloud-based diagnostic platforms that enable remote cancer screening. Regulatory bodies are increasingly supporting innovation through expedited approval pathways and digital health initiatives. These developments are creating fertile ground for market growth and cross-sector collaboration.

Threat:

Risk of false positives/negatives

False positives can lead to unnecessary treatments and psychological distress, while false negatives may delay life-saving interventions. Variability in test sensitivity and specificity across platforms contributes to inconsistent outcomes. AI algorithms, while promising, require rigorous validation to ensure clinical reliability. Regulatory agencies are tightening standards around diagnostic performance and data transparency. Addressing these risks is vital to maintaining trust and ensuring the safe integration of emerging technologies.

Covid-19 Impact:

The COVID-19 pandemic disrupted cancer diagnostic services, delaying screenings and reducing patient throughput. Lockdowns and resource reallocation strained laboratory operations and supply chains, leading to test shortages. However, the crisis accelerated the adoption of remote diagnostics, telepathology, and AI-driven triage systems. Emergency use authorizations enabled faster deployment of innovative diagnostic tools during the pandemic. Post-COVID strategies now emphasize resilience, automation, and decentralized testing models. These shifts are reshaping the cancer diagnostics landscape with a stronger focus on digital transformation and preparedness.

The consumables segment is expected to be the largest during the forecast period

The consumables segment is expected to account for the largest market share during the forecast period, due to its indispensable role in routine diagnostic procedures. Reagents, assay kits, and sample preparation tools are critical for molecular and immunohistochemical testing. Continuous innovation in reagent formulations and microfluidic cartridges is enhancing test sensitivity and throughput. The rise of personalized medicine is driving demand for specialized consumables tailored to individual cancer profiles. Automation in laboratory workflows is boosting consumable usage across centralized and decentralized settings. As diagnostic volumes increase globally, consumables remain the backbone of cancer testing infrastructure.

The hospitals & clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals & clinics segment is predicted to witness the highest growth rate, driven by their central role in cancer diagnosis and treatment. These facilities are rapidly adopting advanced imaging systems, AI-based pathology tools, and integrated diagnostic platforms. The push for early detection and precision oncology is fueling investment in in-house diagnostic capabilities. Hospitals are also leveraging cloud-based data analytics to streamline workflows and enhance diagnostic accuracy. Emerging trends include hybrid diagnostic labs and multidisciplinary cancer centers equipped with real-time decision support systems. As patient volumes rise, hospitals and clinics are becoming hubs for innovation in cancer diagnostics.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising cancer prevalence. Countries like China, India, and Japan are investing heavily in diagnostic modernization and local manufacturing. Government initiatives are promoting early cancer screening and subsidizing advanced diagnostic technologies. The region is witnessing rapid adoption of AI-assisted imaging and portable diagnostic devices. Strategic collaborations between global tech firms and regional healthcare providers are accelerating innovation and market penetration.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, fueled by its leadership in diagnostic innovation and research funding. The U.S. and Canada are pioneering developments in genomic profiling, AI-powered diagnostics, and smart laboratory systems. Regulatory agencies are streamlining approval processes for cutting-edge diagnostic tools, encouraging faster market entry. Hospitals are integrating IoT and cloud-based platforms to enhance diagnostic precision and operational efficiency. The region benefits from a robust reimbursement ecosystem and high adoption of personalized medicine. As cancer care becomes increasingly data-driven, North America continues to set global benchmarks in diagnostic excellence.

Key players in the market

Some of the key players in Advanced Cancer Diagnostics Market include F. Hoffmann-La Roche Ltd., bioMerieux SA, Thermo Fisher Scientific Inc., Medtronic plc, Abbott Laboratories, Becton, Dickinson and Company (BD), Illumina Inc., Myriad Genetics Inc., GE Healthcare, Guardant Health, Siemens Healthineers, Qiagen N.V., Bio-Rad Laboratories Inc., Hologic Inc., and Agilent Technologies Inc.

Key Developments:

In September 2025, Roche announced that it has entered into a definitive merger agreement to acquire 89bio, Inc. (Nasdaq: ETNB), a publicly listed clinical-stage biopharmaceutical company pioneering the development of innovative therapies for the treatment of liver and cardiometabolic diseases. 89bio's pegozafermin is a FGF21 analog currently in late-stage development for MASH in moderate and severe fibrotic patients as well as cirrhotic patients.

In June 2025, bioMerieux announced an agreement to acquire the assets of Day Zero Diagnostics, a US-based infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic-resistant infections. This strategic acquisition aims to enhance bioMerieux's capabilities in next-generation sequencing (NGS) and rapid diagnostics, further solidifying its commitment to advancing healthcare and Antimicrobial Stewardship through innovative solutions.

Product Types Covered:

  • Instruments
  • Consumables
  • Software and Services
  • Other Product Types

Cancer Types Covered:

  • Breast Cancer
  • Liver Cancer
  • Lung Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Ovarian Cancer
  • Prostate Cancer
  • Other Cancers

Technologies Covered:

  • Imaging Techniques
  • Molecular Diagnostics
  • Immunoassays
  • Liquid Biopsy
  • Other Technologies

Distribution Channels Covered:

  • Direct Sales
  • Distributors & Dealers
  • Online Platforms

Applications Covered:

  • Early Cancer Screening
  • Recurrence & Minimal Residual Disease (MRD) Detection
  • Diagnostic & Prognostic Testing
  • Companion Diagnostics
  • Therapy Selection & Monitoring
  • Other Applications

End Users Covered:

  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Diagnostic Laboratories
  • Cancer Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Technology Analysis
  • 3.8 Application Analysis
  • 3.9 End User Analysis
  • 3.10 Emerging Markets
  • 3.11 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Advanced Cancer Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Instruments
    • 5.2.1 Imaging Systems
    • 5.2.2 Pathology-based Instruments
    • 5.2.3 Molecular Diagnostic Platforms
  • 5.3 Consumables
    • 5.3.1 Kits & Reagents
    • 5.3.2 Assay Panels
  • 5.4 Software & Services
    • 5.4.1 Data Analytics Tools
    • 5.4.2 Diagnostic Services
  • 5.5 Other Product Types

6 Global Advanced Cancer Diagnostics Market, By Cancer Type

  • 6.1 Introduction
  • 6.2 Breast Cancer
  • 6.3 Liver Cancer
  • 6.4 Lung Cancer
  • 6.5 Cervical Cancer
  • 6.6 Colorectal Cancer
  • 6.7 Ovarian Cancer
  • 6.8 Prostate Cancer
  • 6.9 Other Cancers

7 Global Advanced Cancer Diagnostics Market, By Technology

  • 7.1 Introduction
  • 7.2 Imaging Techniques
    • 7.2.1 MRI
    • 7.2.2 PET/CT
    • 7.2.3 CT Scan
    • 7.2.4 Ultrasound
    • 7.2.5 Mammography
  • 7.3 Molecular Diagnostics
    • 7.3.1 PCR
    • 7.3.2 Microarrays
    • 7.3.3 Next-Generation Sequencing (NGS)
    • 7.3.4 In Situ Hybridization (ISH)
  • 7.4 Immunoassays
    • 7.4.1 ELISA
    • 7.4.2 Immunohistochemistry (IHC)
  • 7.5 Liquid Biopsy
    • 7.5.1 Circulating Tumor Cells (CTCs)
    • 7.5.2 Circulating Tumor DNA (ctDNA)
    • 7.5.3 Exosomes
  • 7.6 Other Technologies

8 Global Advanced Cancer Diagnostics Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Direct Sales
  • 8.3 Distributors & Dealers
  • 8.4 Online Platforms

9 Global Advanced Cancer Diagnostics Market, By Application

  • 9.1 Introduction
  • 9.2 Early Cancer Screening
  • 9.3 Recurrence & Minimal Residual Disease (MRD) Detection
  • 9.4 Diagnostic & Prognostic Testing
  • 9.5 Companion Diagnostics
  • 9.6 Therapy Selection & Monitoring
  • 9.7 Other Applications

10 Global Advanced Cancer Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals & Clinics
  • 10.3 Ambulatory Care Centers
  • 10.4 Diagnostic Laboratories
  • 10.5 Cancer Research Institutes
  • 10.6 Other End Users

11 Global Advanced Cancer Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 F. Hoffmann-La Roche Ltd.
  • 13.2 bioMerieux SA
  • 13.3 Thermo Fisher Scientific Inc.
  • 13.4 Medtronic plc
  • 13.5 Abbott Laboratories
  • 13.6 Becton, Dickinson and Company (BD)
  • 13.7 Illumina Inc.
  • 13.8 Myriad Genetics Inc.
  • 13.9 GE Healthcare
  • 13.10 Guardant Health
  • 13.11 Siemens Healthineers
  • 13.12 Qiagen N.V.
  • 13.13 Bio-Rad Laboratories Inc.
  • 13.14 Hologic Inc.
  • 13.15 Agilent Technologies Inc.

List of Tables

  • Table 1 Global Advanced Cancer Diagnostics Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Advanced Cancer Diagnostics Market Outlook, By Product Type (2024-2032) ($MN)
  • Table 3 Global Advanced Cancer Diagnostics Market Outlook, By Instruments (2024-2032) ($MN)
  • Table 4 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Systems (2024-2032) ($MN)
  • Table 5 Global Advanced Cancer Diagnostics Market Outlook, By Pathology-based Instruments (2024-2032) ($MN)
  • Table 6 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostic Platforms (2024-2032) ($MN)
  • Table 7 Global Advanced Cancer Diagnostics Market Outlook, By Consumables (2024-2032) ($MN)
  • Table 8 Global Advanced Cancer Diagnostics Market Outlook, By Kits & Reagents (2024-2032) ($MN)
  • Table 9 Global Advanced Cancer Diagnostics Market Outlook, By Assay Panels (2024-2032) ($MN)
  • Table 10 Global Advanced Cancer Diagnostics Market Outlook, By Software & Services (2024-2032) ($MN)
  • Table 11 Global Advanced Cancer Diagnostics Market Outlook, By Data Analytics Tools (2024-2032) ($MN)
  • Table 12 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Services (2024-2032) ($MN)
  • Table 13 Global Advanced Cancer Diagnostics Market Outlook, By Other Product Types (2024-2032) ($MN)
  • Table 14 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Type (2024-2032) ($MN)
  • Table 15 Global Advanced Cancer Diagnostics Market Outlook, By Breast Cancer (2024-2032) ($MN)
  • Table 16 Global Advanced Cancer Diagnostics Market Outlook, By Liver Cancer (2024-2032) ($MN)
  • Table 17 Global Advanced Cancer Diagnostics Market Outlook, By Lung Cancer (2024-2032) ($MN)
  • Table 18 Global Advanced Cancer Diagnostics Market Outlook, By Cervical Cancer (2024-2032) ($MN)
  • Table 19 Global Advanced Cancer Diagnostics Market Outlook, By Colorectal Cancer (2024-2032) ($MN)
  • Table 20 Global Advanced Cancer Diagnostics Market Outlook, By Ovarian Cancer (2024-2032) ($MN)
  • Table 21 Global Advanced Cancer Diagnostics Market Outlook, By Prostate Cancer (2024-2032) ($MN)
  • Table 22 Global Advanced Cancer Diagnostics Market Outlook, By Other Cancers (2024-2032) ($MN)
  • Table 23 Global Advanced Cancer Diagnostics Market Outlook, By Technology (2024-2032) ($MN)
  • Table 24 Global Advanced Cancer Diagnostics Market Outlook, By Imaging Techniques (2024-2032) ($MN)
  • Table 25 Global Advanced Cancer Diagnostics Market Outlook, By MRI (2024-2032) ($MN)
  • Table 26 Global Advanced Cancer Diagnostics Market Outlook, By PET/CT (2024-2032) ($MN)
  • Table 27 Global Advanced Cancer Diagnostics Market Outlook, By CT Scan (2024-2032) ($MN)
  • Table 28 Global Advanced Cancer Diagnostics Market Outlook, By Ultrasound (2024-2032) ($MN)
  • Table 29 Global Advanced Cancer Diagnostics Market Outlook, By Mammography (2024-2032) ($MN)
  • Table 30 Global Advanced Cancer Diagnostics Market Outlook, By Molecular Diagnostics (2024-2032) ($MN)
  • Table 31 Global Advanced Cancer Diagnostics Market Outlook, By PCR (2024-2032) ($MN)
  • Table 32 Global Advanced Cancer Diagnostics Market Outlook, By Microarrays (2024-2032) ($MN)
  • Table 33 Global Advanced Cancer Diagnostics Market Outlook, By Next-Generation Sequencing (NGS) (2024-2032) ($MN)
  • Table 34 Global Advanced Cancer Diagnostics Market Outlook, By In Situ Hybridization (ISH) (2024-2032) ($MN)
  • Table 35 Global Advanced Cancer Diagnostics Market Outlook, By Immunoassays (2024-2032) ($MN)
  • Table 36 Global Advanced Cancer Diagnostics Market Outlook, By ELISA (2024-2032) ($MN)
  • Table 37 Global Advanced Cancer Diagnostics Market Outlook, By Immunohistochemistry (IHC) (2024-2032) ($MN)
  • Table 38 Global Advanced Cancer Diagnostics Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
  • Table 39 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor Cells (CTCs) (2024-2032) ($MN)
  • Table 40 Global Advanced Cancer Diagnostics Market Outlook, By Circulating Tumor DNA (ctDNA) (2024-2032) ($MN)
  • Table 41 Global Advanced Cancer Diagnostics Market Outlook, By Exosomes (2024-2032) ($MN)
  • Table 42 Global Advanced Cancer Diagnostics Market Outlook, By Other Technologies (2024-2032) ($MN)
  • Table 43 Global Advanced Cancer Diagnostics Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 44 Global Advanced Cancer Diagnostics Market Outlook, By Direct Sales (2024-2032) ($MN)
  • Table 45 Global Advanced Cancer Diagnostics Market Outlook, By Distributors & Dealers (2024-2032) ($MN)
  • Table 46 Global Advanced Cancer Diagnostics Market Outlook, By Online Platforms (2024-2032) ($MN)
  • Table 47 Global Advanced Cancer Diagnostics Market Outlook, By Application (2024-2032) ($MN)
  • Table 48 Global Advanced Cancer Diagnostics Market Outlook, By Early Cancer Screening (2024-2032) ($MN)
  • Table 49 Global Advanced Cancer Diagnostics Market Outlook, By Recurrence & Minimal Residual Disease (MRD) Detection (2024-2032) ($MN)
  • Table 50 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic & Prognostic Testing (2024-2032) ($MN)
  • Table 51 Global Advanced Cancer Diagnostics Market Outlook, By Companion Diagnostics (2024-2032) ($MN)
  • Table 52 Global Advanced Cancer Diagnostics Market Outlook, By Therapy Selection & Monitoring (2024-2032) ($MN)
  • Table 53 Global Advanced Cancer Diagnostics Market Outlook, By Other Applications (2024-2032) ($MN)
  • Table 54 Global Advanced Cancer Diagnostics Market Outlook, By End User (2024-2032) ($MN)
  • Table 55 Global Advanced Cancer Diagnostics Market Outlook, By Hospitals & Clinics (2024-2032) ($MN)
  • Table 56 Global Advanced Cancer Diagnostics Market Outlook, By Ambulatory Care Centers (2024-2032) ($MN)
  • Table 57 Global Advanced Cancer Diagnostics Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
  • Table 58 Global Advanced Cancer Diagnostics Market Outlook, By Cancer Research Institutes (2024-2032) ($MN)
  • Table 59 Global Advanced Cancer Diagnostics Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.